Pharmaceutical companies last year launched new U.S. drugs at prices 35% higher than in 2022, reflecting in part the industry's embrace of expensive therapies for rare.
Italy has spent around 45% of the almost 102 billion euros ($110.7 billion) it has received so far from European Union COVID-19 recovery funds, short of a target set in.